Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design
Study context
- Population
- Patients with LV systolic dysfunction (left ventricular ejection fraction (LVEF) <45% by cardiovascular magnetic resonance (CMR)) ≥12 h and ≤14 days after acute myocardial infarction (MI)
- Participants
- 100 patients
- Planned comparison
- Empagliflozin vs placebo
- Primary endpoint
- Change in LV end-systolic volume indexed to body surface area
- Follow-up
- 24 weeks from randomization
Methodological detailsrationale and design, double-blind, placebo-controlled, multicentre, Secondary endpoints: LV and atrial volumes, LV mass, LVEF, circulating cardiac biomarkers
- Rationale and design
- Double-blind
- Placebo-controlled
- Multicentre
- Secondary endpoints: LV and atrial volumes, LV mass, LVEF, circulating cardiac biomarkers
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design. ESC Heart Fail. Published 7 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →